Researc for the biomarkers of invasion and recurrence in nasopharyngeal carcinoma and the functional validation

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900024704

Enrollment

Unknown

Registered

2019-07-22

Start date

2019-07-25

Completion date

Unknown

Last updated

2019-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nasopharyngeal carcinoma

Interventions

Gold Standard:Pathologic diagnosis.

Index test:40&#32

candidate&#32

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The serum samples of nasopharyngeal carcinoma must meet the following inclusion criteria: 1. First pathological diagnosis of nasopharyngeal carcinoma; 2. The family member or the patient has signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. has received anti-cancer treatment; 2. with a history of other malignant tumors.

Design outcomes

Primary

Measure	Time frame
microRNA;SEN, SPE, ACC, AUC of ROC;	—

Countries

China

Contacts

Public ContactYongqing Lai

Peking University Shenzhen Hospital

yqlord@outlook.com+86 13500058425

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026